Characteristics of human immunodeficiency virus-1 infected children receiving Highly active antiretroviral therapy: a cross-sectional study

被引:1
作者
Badillo, K. [1 ]
Prieto, L. [1 ]
Toledano, M. [1 ]
Guillen, S. [1 ]
Alvarez, A. [1 ]
Garcia Bermejo, I. [1 ]
Ramos Amador, J. T. [1 ]
机构
[1] Hosp Univ Getafe, Serv Pediat, Madrid, Spain
来源
ANALES DE PEDIATRIA | 2012年 / 76卷 / 06期
关键词
Highly active antiretroviral therapy; Human immunodeficiency virus infected children; Immune control; Metabolic toxicity; Virological control; HIV-INFECTION; TRANSMISSION; SURVIVAL;
D O I
10.1016/j.anpedi.2011.12.005
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Introduction: Since 1996, when HAART became available, there has been a change in the course of HIV-infection, leading it to become a chronic disease. Our aim was to describe the characteristics of the children followed up in our hospital. Patients and methods: A cross-sectional study was conducted on 32 HIV-infected children followed up until December-2010, at the University-Hospital de Getafe. Clinical and laboratory information from the last visit was collected for the evaluation of patients. Results: Thirty-two children with HIV-1 were evaluated, 29 infected through vertical-transmission. The median age was 14 years. According to the CDC classification, 56% (18/32) of children were in category A, 28% (9/32) B and 16% (5/32) C. Immunological class was 3 in 75% of children, class 2 in 9% and class 1 in 16%. The median nadir of CD4 was 337 cells/ml (12%). The median current CD4 was 749 (31%). Only one adolescent had a CD4% below 200 cells/ml due to lack of adherence. Twenty-eight patients (87%) were receiving HAART, and 4 patients were off antiretroviral treatment. Among the patients treated, 26 (93%) had viral loads <200copies/ml. The median viral-load was <20 copies/ml. Median time on antiretroviral treatment was 10 years. The combination more frequently used was two nucleoside reverse transcriptase inhibitors (NRTI) and one protease inhibitor (PI), that was given to 15 patients (47%), followed by 2 NRTI, and one non-nucleoside reverse transcriptase inhibitor (NNRTI) in 8 patients (29%). Two children received rescue therapy including raltegravir, one with tipranavir and the other with darunavir. A total of 12 patients (43%) received medication once a day, 7 of them with fixed-dose combinations in a single tablet (25%). There were metabolic complications, including hyperlipidaemia or lipodystrophy were observed in 17 children (53%). Conclusions: Most of our patients are receiving HAART, with good virological and immunological control. The prevalence of metabolic abnormalities was high. Strategies to improve adherence and decrease toxicities are needed in perinatally-acquired HIV-infected children. (C) 2011 Asociacion Espanola de Pediatria. Published by Elsevier Espana, S.L. All rights reserved.
引用
收藏
页码:317 / 323
页数:7
相关论文
共 20 条
[1]  
[Anonymous], Vigilancia epidemiologica das infecoes associadas aos cuidados de saude - criterios do CDC para definicoes de infecoes nos cuidados de agudos - PNCI - 2009
[2]  
[Anonymous], INFORM PANDEMIA MUND
[3]   REDUCTION OF MATERNAL-INFANT TRANSMISSION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 WITH ZIDOVUDINE TREATMENT [J].
CONNOR, EM ;
SPERLING, RS ;
GELBER, R ;
KISELEV, P ;
SCOTT, G ;
OSULLIVAN, MJ ;
VANDYKE, R ;
BEY, M ;
SHEARER, W ;
JACOBSON, RL ;
JIMENEZ, E ;
ONEILL, E ;
BAZIN, B ;
DELFRAISSY, JF ;
CULNANE, M ;
COOMBS, R ;
ELKINS, M ;
MOYE, J ;
STRATTON, P ;
BALSLEY, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (18) :1173-1180
[4]   New challenges in therapeutic management of human immunodeficiency Virus-infected children [J].
Faye, A. .
ARCHIVES DE PEDIATRIE, 2007, 14 (02) :212-218
[5]   Lower mother-to-child HIV-1 transmission in boys is independent of type of delivery and antiretroviral prophylaxis - The Italian Register for HIV Infection in Children [J].
Galli, L ;
Puliti, D ;
Chiappini, E ;
Gabiano, C ;
Tovo, PA ;
Pezzotti, P ;
de Martino, M .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2005, 40 (04) :479-485
[6]   Adherence to prescribed antiretroviral therapy in human immunodeficiency virus-infected children in the PENTA 5 trial [J].
Gibb, DM ;
Goodall, RL ;
Giacomet, V ;
McGee, L ;
Compagnucci, A ;
Lyall, H .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2003, 22 (01) :56-62
[7]   Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected children [J].
Granados, JMS ;
Amador, JTR ;
De Miguel, SF ;
Tomé, MIG ;
Conejo, PR ;
Vivas, PF ;
Pollán, JC ;
Contreras, JR ;
Espert, AN .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2003, 22 (10) :863-867
[8]   Morbidity, mortality, and response to treatment by children in the United Kingdom and Ireland with perinatally acquired HIV infection during 1996-2006: Planning for teenage and adult care [J].
Judd, Ali ;
Doerholt, Katja ;
Tookey, Pat A. ;
Sharland, Mike ;
Riordan, Andrew ;
Menson, Esse ;
Novelli, Vas ;
Lyall, E. G. Hermione ;
Masters, Janet ;
Tudor-Williams, Gareth ;
Duong, Trinh ;
Gibb, Di M. .
CLINICAL INFECTIOUS DISEASES, 2007, 45 (07) :918-924
[9]   Antiretroviral therapy in HIV-infected children: The metabolic cost of improved survival [J].
Leonard, EG ;
McComsey, GA .
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2005, 19 (03) :713-+
[10]   Metabolic complications of antiretroviral therapy in children [J].
Leonard, EG ;
McComsey, GA .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2003, 22 (01) :77-84